Kallistatin as a new non-invasive marker in patients with non-alcoholicfattyliver disease combined with hypertension

Abstract

Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH).